Royalty Pharma — Q3 2026 Earnings Summary

Royalty Pharma reported third quarter 2026 results with Portfolio Receipts growing 9% to $890 million and Royalty Receipts increasing 9% to $883 million. The company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3,500 million to $3,550 million, reflecting expected Royalty Receipts growth of 10% to 11%. Key drivers for the quarter included strong performance from Tremfya, Voranigo, Evrysdi, and Imdelltra, alongside the acquisition of royalties on Zoryve and Mimrylo. Additionally, the company announced $1.9 billion in transaction value and highlighted positive regulatory milestones for products such as Rasonque, Weltruza, and Imdelltra.